Navigation Links
David Barker, Former Illumina CSO, Joins GenVault's Scientific Advisory Board
Date:9/28/2007

CARLSBAD, Calif., Sept. 28 /PRNewswire/ -- GenVault Corporation today announces that industry expert David Barker Ph.D. has joined its Scientific Advisory Board. In his role on the board, Dr. Barker will provide scientific guidance facilitating GenVault's entry into new biosample management markets. Dr. Barker brings more than 20 years experience in life science product commercialization as well as experience in serving on the boards of companies such as NextBio, Cell Biosciences, and Microchip Biotechnologies.

"Dr. Barker's extraordinarily deep understanding of the industry and its future will be extremely valuable as we chart our vision. We are very honored to welcome Dr. Barker as a key member of the GenVault advisory team," said David Wellis, CEO of GenVault

"Well-characterized biological samples and their intelligent storage and retrieval are essential for discovering disease genes and biomarkers. I am pleased to be asked to participate in GenVault's creative solutions for sample management " said Dr. Barker

Dr. Barker's previous product commercialization experience includes senior positions at Illumina as Vice President and Chief Scientific Officer; Amersham Biosciences as Vice President and Chief Science Advisor and Molecular Dynamics as Vice President of Research and Business Development until its acquisition by Amersham Biosciences. In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a BS with honors in Chemistry from the California Institute of Technology and a PhD in Biochemistry from Brandeis University.

About GenVault

GenVault is redefining the global standard in biosample workflow and storage solutions for genomic medicine, discovery and identification. The company's room temperature technology reduces costs and empowers its partners to maximize their most valuable assets. As a scalable and reliable alternative to traditional freezers and DNA purification systems, GenVault's dry-state platform enables the extraction, preservation, recovery and distribution of DNA at room temperature. Future systems will also accommodate proteins and RNA to provide a comprehensive solution. For more information visit us at http://www.genvault.com.

EDITORIAL CONTACTS:

David Wellis, GenVault

(760) 268-5256

dwellis@genvault.com


'/>"/>
SOURCE GenVault Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Germantown drug company hires pharma veteran James Davidson as COO
2. David Brooks: Segmented nation looks for solidarity amid IT-powered niches
3. CIO Leadership Series: Rick Davidson, Manpower
4. CIO Leadership Series: David Melbye, Milwaukee Metro Sewerage District
5. CIO Leadership Series: David Cagigal, Alliant Energy
6. Former Fiserv exec to enter Business Hall of Fame
7. UW scientist, former WiCell director found stem cell company
8. Kyron appoints former AMA chairman to board
9. Genzyme sues former Bone Care employees
10. Former astronaut a leader in Wisconsin Spaceport
11. New book from former CDC CEO walks readers through innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2016 Amgen (NASDAQ: AMGN ) and ... submission of a Marketing Authorization Application (MAA) to the European ... Avastin ® (bevacizumab). The companies believe this submission is ... "The submission of ABP 215 to the EMA ... oncology portfolio," said Sean E. Harper , M.D., executive ...
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... ACEA Biosciences, ... its Phase I/II clinical trials for AC0010 at the World Conference on Lung Cancer ... providing an update on the phase I/II clinical trials for AC0010 in patients with ...
(Date:12/2/2016)... ... December 01, 2016 , ... PhUSE will build on the ... US Single Day Events (SDE) to organize a multiple-day US conference. The first ... Topics of the pharmaceutical and life sciences industry will cover industry standards, data ...
(Date:12/2/2016)... ... December 01, 2016 , ... Orthogonal, ... on their recent FDA Class II 510(k) clearance for their flagship medical device, ... commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. While other companies ...
Breaking Biology Technology:
(Date:12/2/2016)... Dec. 1, 2016   SoftServe , a ... BioLock , an electrocardiogram (ECG) biosensor analysis system ... key IoT asset. The smart system ensures device-to-device ... steering wheel and mobile devices to easily ,recognize, ... As vehicle technology advances, so too must ...
(Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a ... point-of-care products for the objective detection of concussion and ... company has successfully completed a meeting with the U.S. ... Tbit™ blood test Pre-Submission Package. During the meeting company ... system as a precursor to commencement of a planned ...
(Date:11/28/2016)... "The biometric system market ... The biometric system market is in the growth stage ... future. The biometric system market is expected to be ... CAGR of 16.79% between 2016 and 2022. Government initiative ... in smartphones, rising use of biometric technology in financial ...
Breaking Biology News(10 mins):